ArticlePloS one2015
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Association of Mean Corpuscular Hemoglobin Concentration With Mortality in Patients With Cancer.Cureus · 2026Article
- Association between baseline hemoglobin levels and pathological complete response in 404 female breast cancer patients undergoing neoadjuvant therapy in Western Guangdong region: a retrospective cohort study.Frontiers in oncology · 2026Article
- Addressing conceptual and design gaps in the oncology nutrition evidence base during chemotherapy: contributions of the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes Consortium.Journal of the National Cancer Institute · 2025Article
- Constructing and evaluating a predictive model for the risk of preoperative frailty in breast cancer patients.BMC women's health · 2025Article
- Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy.Immunotherapy · 2025Article
- The Importance of Hypoxia-Related to Hemoglobin Concentration in Breast Cancer.Cell biochemistry and biophysics · 2024Review
- [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.European journal of nuclear medicine and molecular imaging · 2023Article
- Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study.World journal of gastrointestinal oncology · 2023Article
- Incidence of anemia and red blood cell (RBC) transfusion requirement in breast cancer.Caspian journal of internal medicine · 2023Article
- Article
- Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.JAMA network open · 2021Article
- Experimental Drugs for Chemotherapy- and Cancer-Related Anemia.Journal of experimental pharmacology · 2021Review
- Article
- Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach.Frontiers in physiology · 2018Review
- Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer.PloS one · 2016Article
- The Prognostic Significance of Preoperative Anemia in Gastric Cancer Patients.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia related to adjuvant chemotherapy might predict compromised survival in patients with breast cancer. The present population-based study was to investigate the correlation of pretreatment anemia with pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy (NCT).
methodsFrom 1999 to 2011, a total of 655 patients with operable or locally advanced breast cancer who underwent NCT before definitive surgery were reviewed. The patients were subdivided into anemic (baseline hemoglobin (Hb)<12.0 g/dL) and non-anemic (Hb≥12.0 g/dL) groups. Comparison was made between anemic and non-anemic groups concerning the rate of pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Logistic and Cox regression models were utilized to determine the predictive value of pretreatment anemia in outcomes of patients undergoing NCT.
results166 women (25.3%) were anemic before treatment. Patients in the anemic group were less likely to achieve pCR in NCT than their non-anemic counterparts (odds ratio (OR) 0.428, 95% confidence interval (CI) 0.198-0.927, p = 0.031). Patients with baseline anemia displayed inferior 10-year RFS (59.1% vs 66.0%, p = 0.022 by log-rank), OS (75.3% vs 90.9%, p<0.001) and CSS (82.4% vs 94.4%, p<0.001) compared with those without. After adjustment for confounders, pretreatment anemia was demonstrated to correlate with elevated risk of relapse (hazard ratio (HR) 1.453, 95% CI 1.077-1.962, p = 0.015), cancer-specific mortality (HR 2.961, 95% CI 1.679-5.222, p<0.001) and all-cause mortality (HR 2.873, 95% CI 1.757-4.699, p<0.001).
conclusionsPretreatment anemia was associated with worse pathological response to NCT as well as survival status in breast cancer. Further studies are warranted to identify optimal interventions and improve the prognosis of this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.